Literature DB >> 10906650

Treatment of nonmelanotic hyperpigmentation with the Q-switched ruby laser.

P M Becker-Wegerich1, A Kuhn, L Malek, P Lehmann, M Megahed, T Ruzicka.   

Abstract

Hyperpigmentation of the skin is often refractory to conventional therapies, but has significant cosmetic implications if located on visible areas. Because laser systems are capable of removing pigment deposits caused by selective photothermolysis, we addressed the issue of whether the Q-switched ruby laser could be a useful alternative in the treatment of nonmelanotic hyperpigmented skin lesions. We report the successful treatment of a patient with hyperpigmentation caused by iatrogenic human herpesvirus 8-associated Kaposi's sarcoma and a patient with hyperpigmentation caused by long-term antimalarial therapy for cutaneous lupus erythematosus. In both patients, clinical lightening of the darkly pigmented lesions was seen after a single treatment, and a significant improvement was observed after 3 laser applications. The patients tolerated the laser therapy well without any short-term side effects and did not experience either scarring or considerable textural skin changes. Histologic examination was performed before and after laser treatment to confirm the reduction of the pigment deposits. Our data indicate that treatment of nonmelanotic skin hyperpigmentation with the Q-switched ruby laser might be a safe and powerful therapeutic method.

Entities:  

Mesh:

Year:  2000        PMID: 10906650     DOI: 10.1067/mjd.2000.105555

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  2 in total

1.  Hydroxychloroquine-related skin discoloration.

Authors:  Jérôme Coulombe; Olivia Boccara
Journal:  CMAJ       Date:  2016-02-22       Impact factor: 8.262

Review 2.  Systemic toxicity of chloroquine and hydroxychloroquine: prevalence, mechanisms, risk factors, prognostic and screening possibilities.

Authors:  Romain Muller
Journal:  Rheumatol Int       Date:  2021-04-24       Impact factor: 2.631

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.